Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the feasibility of pharmacokinetically boosting
osimertinib using cobicistat in order to improve osimertinib exposure in individual patients
with advanced NSCLC with mutated EGFR. The main questions it aims to answer are:
- Cohort 1: Does concurrent use of osimertinib and cobicistat allow for osimertinib weekly
intake reductions? If so, how much can the intake be reduced while retaining clinically
effective exposure?
- Cohort 2: Does concurrent use of osimertinib and cobicistat allow for improved
penetration of osimertinib in the central nervous system, in patients with CNS
oligoprogression?
Participants who are taking osimertinib in regular care will receive cobicistat in addition
to their other medication. They will undergo blood sampling to measure the amount of
osimertinib in blood, and measure the effect of boosting. Additionally, in cohort 1 patients
will be dose-reduced if their exposure levels allow.